未登录 分享 收藏
分享 收藏
分享 收藏
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations Le, Xiuning; Spira, Alexander; Gadgeel, Shirish; Yu, Yan; Zhao, Yanqiu; Cheng, Ying; Riess, Jonathan; Juan-Vidal, Oscar; Gao, Bo; Yoh, Kiyotaka; Forster, Martin; Kitazono, Satoru; Hayashi, Hidetoshi; Planchard, David; Jiang, Yong; Huang, Jack; Baio, Nichole; Kowanetz, Marcin; Wang, Shirley; Leung, William; Hsu, Jerry Y.; Wang, Jie 分享 收藏
FURVENT, Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004) Spira, Alexander; Cho, Byoung Chul; Felip, Enriqueta; Garon, Edward; Goto, Koichi; Johnson, Melissa Lynne; Leighl, Natasha B.; Passaro, Antonio; Planchard, David; Popat, Sanjay; Yang, James; Lu, Xiaoqian; Jiang, Yong; Huang, Jack; Lam, Morgan; Kowanetz, Marcin; Wang, Shirley; Le, John; Hsu, Jerry; Zhou, Caicun 分享 收藏
Furmonertinib is a brain-penetrant EGFR TKI highly active in uncommon EGFR mutations, including PACC and exon 20 insertions Nilsson, Monique B.; Mounir, Zineb; Musib, Luna; He, Junqin; Yu, Xiaoxing; Li, Qing; Luo, Huibing; Heymach, John V.; Hsu, Jerry Y.; Lutzker, Stuart; Le, Xiuning; Kowanetz, Marcin 分享 收藏
分享 收藏
Childhood-Onset Chorea Caused by a Recurrent De Novo DRD2 Variant Mencacci, Niccolo E.; Steel, Dora; Magrinelli, Francesca; Hsu, Jerry; Sarmiento, Ignacio Juan Keller; Schifferli, Monica Troncoso; Munoz, Daniela; Stefanis, Leonidas; Lubbe, Steven J.; Wood, Nicholas W.; Kurian, Manju A.; Stamelou, Maria 分享 收藏
分享 收藏
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial Dent, S.; Cortes, J.; Im, Y-H; Dieras, V; Harbeck, N.; Krop, I. E.; Wilson, T. R.; Cui, N.; Schimmoller, F.; Hsu, J. Y.; He, J.; De Laurentiis, M.; Sousa, S.; Drullinsky, P.; Jacot, W. 分享 收藏
Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer Jacot, W.; Savage, H. M.; Dent, S.; Cortes, J.; Im, Y-H.; Dieras, V. C.; Harbeck, N.; Krop, I. E.; Chen, J.; Sokol, E.; Schimmoller, F.; Hsu, J.; De Laurentiis, M.; Wilson, T. R. 分享 收藏
Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC) Saura, C.; de Azambuja, E.; Hlauschek, D.; Oliveira, M.; Zardavas, D.; Jallitsch-Halper, A.; de la Pena, L.; Nuciforo, P.; Ballestrero, A.; Fornier, M. N.; Boer, K.; Ciruelos, E.; Valero, V.; Wilson, T. R.; Stout, T. J.; Hsu, J. Y.; Shi, Y.; Piccart, M.; Gnant, M.; Baselga, J. 分享 收藏
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors 口服PI3K抑制剂Taselisib在晚期实体瘤患者中的I期剂量递增研究 Juric, Dejan; Krop, Ian; Ramanathan, Ramesh K.; Wilson, Timothy R.; Ware, Joseph A.; Bohorquez, Sandra M. Sanabria; Savage, Heidi M.; Sampath, Deepak; Salphati, Laurent; Lin, Ray S.; Jin, Huan; Parmar, Hema; Hsu, Jerry Y.; Von Hoff, Daniel D.; Baselga, Jose 分享 收藏
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours Baselga, J.; Cortes Castan, J.; De Laurentiis, M.; Dieras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y-H.; Jacot, W.; Krop, I. E.; Verma, S. 分享 收藏
Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignancies Wilson, Timothy R.; Savage, Heidi; Aimi, Junko; Jin, Jessica; Parmar, Hema; Hsu, Jerry; Krop, Ian; Saura, Cristina; Cervantes, Andres; Sachdev, Jasgit; Patel, Manish; Cejalvo, Juan; Oliveira, Mafalda; Winer, Eric; Von Hoff, Daniel; Baselga, Jose; Juric, Dejan 分享 收藏
LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer Saura, Cristina; de Azambuja, Evandro; Dubsky, Peter; Oliveira, Mafalda; Saini, Kamal S.; Fes, Christian; Lin, Ray S.; Wilson, Timothy R.; Fredickson, Jill; Parmar, Hema; Hsu, Jerry Y.; Piccard, Martine; Gnant, Michael; Baselga, Jose 分享 收藏
Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer Saura, Cristina; Sachdev, Jasgit; Patel, Manish R.; Cervantes, Andres; Juric, Dejan; Infante, Jeffrey R.; Richards, Donald; Sanabria, Sandra; Lu, Xuyang; Ware, Joseph; Wilson, Timothy R.; Parmar, Hema; Hsu, Jerry Y.; Oliveira, Mafalda; Winer, Eric P.; Von Hoff, Daniel D.; Baselga, Jose; Krop, Ian E. 分享 收藏
Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor Wilson, Timothy R.; Savage, Heidi; O'Brien, Carol; Sanabria, Sandra; Lin, Ray S.; Wagle, Marie-Claire; Yan, Yibing; Lackner, Mark R.; Parmar, Hema; Hsu, Jerry Y.; Juric, Dejan; Krop, Ian E.; Ramanathan, Ramesh K.; Von Hoff, Daniel D.; Baselga, Jose 分享 收藏
Drug-drug interaction assessment of GDC-0032, a beta-sparing inhibitor of phosphoinositide 3-kinase (PI3K), using midazolam, a sensitive CYP3A4 substrate. Graham, Richard A.; Cheeti, Sravanthi; Salphati, Laurent; Lu, Tong; Kurkjian, Carla; Von Hoff, Daniel; Sachdev, Jasgit; Juric, Dejan; Baselga, Jose; Parmer, Hema; Hsu, Jerry; Infante, Jeffrey 分享 收藏
Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors. Olivero, Alan G.; Heffron, Timothy P.; Baumgardner, Matthew; Belvin, Marcia; Ross, Leanne Berry; Blaquiere, Nicole; Bradley, Erin; Castanedo, Georgette; Derynck, Mika; Do, Steven; Dotson, Jennafer; Dudley, Danette; Edgar, Kyle; Folkes, Adrian; Francis, Ross; Gianetti, Tony; Goldsmith, Richard; Goldsmith, Paul; Guan, Jane; Harrison, Trevor; Heald, Robert; Hsu, Jerry; Jackson, Phillip; Jones, Graham; Kim, Amy; Kolesnikov, Aleks; Lackner, Mark; Lee, Leslie; Lesnick, John; Lewis, Cristina; Mamounas, Michael; McLean, Neville; Murray, Jeremy; Ndubaku, Chudi; Nonomiya, Jim; Pang, Jodie; Pegg, Neil; Prior, Wei Wei; Salphati, Laurent; Sampath, Deepack; Sideris, Stephen; Siu, Michael; Staben, Steven; Sutherlin, Daniel; Ultsch, Mark; Wallin, Jeff; Wang, Lan; Wiesmann, Christian; Zhang, Xiaolin; Friedman, Lori S. 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏